Kyntra Bio, Inc. (KYNB)vsNovartis AG ADR (NVS)
KYNB
Kyntra Bio, Inc.
$7.97
-0.06%
HEALTHCARE · Cap: $34.38M
NVS
Novartis AG ADR
$137.16
-0.23%
HEALTHCARE · Cap: $260.70B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 1228085% more annual revenue ($56.69B vs $4.62M). KYNB leads profitability with a 3969.0% profit margin vs 22.5%. NVS earns a higher WallStSmart Score of 51/100 (C-).
KYNB
Hold46
out of 100
Grade: D+
NVS
Buy51
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for KYNB.
Margin of Safety
-47.0%
Fair Value
$93.29
Current Price
$137.16
$43.87 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Keeps 3969 of every $100 in revenue as profit
Strong operational efficiency at 1192.0%
Revenue surging 36.5% year-over-year
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Strong operational efficiency at 34.6%
Keeps 23 of every $100 in revenue as profit
Generating 5.6B in free cash flow
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
ROE of 0.0% — below average capital efficiency
Negative free cash flow — burning cash
0.8% revenue growth
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : KYNB
The strongest argument for KYNB centers on Profit Margin, Operating Margin, Revenue Growth. Profitability is solid with margins at 3969.0% and operating margin at 1192.0%. Revenue growth of 36.5% demonstrates continued momentum.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 34.6%.
Bear Case : KYNB
The primary concerns for KYNB are EPS Growth, Market Cap, Return on Equity.
Bear Case : NVS
The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.
Key Dynamics to Monitor
KYNB profiles as a growth stock while NVS is a value play — different risk/reward profiles.
KYNB carries more volatility with a beta of 1.04 — expect wider price swings.
KYNB is growing revenue faster at 36.5% — sustainability is the question.
NVS generates stronger free cash flow (5.6B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (51/100 vs 46/100), backed by strong 22.5% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Kyntra Bio, Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
Kyntra Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is headquartered in San Francisco, California.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?